Shyamala Maheswaran
Overview
Explore the profile of Shyamala Maheswaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
15871
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
2.
Burr R, Leshchiner I, Costantino C, Blohmer M, Sundaresan T, Cha J, et al.
Nat Cancer
. 2024 Oct;
5(11):1681-1696.
PMID: 39406916
Although the development of multiple primary tumors in smokers with lung cancer can be attributed to carcinogen-induced field cancerization, the occurrence of multiple tumors at presentation in individuals with EGFR-mutant...
3.
Takahashi M, Chong H, Zhang S, Yang T, Lazarov M, Harry S, et al.
Cell
. 2024 Apr;
187(10):2536-2556.e30.
PMID: 38653237
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown....
4.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
bioRxiv
. 2024 Apr;
PMID: 38559183
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility...
5.
Saylor P, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300230.
PMID: 38354328
Purpose: Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index...
6.
Takahashi M, Chong H, Zhang S, Lazarov M, Harry S, Maynard M, et al.
bioRxiv
. 2023 Nov;
PMID: 37961514
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To...
7.
Burr R, Leshchiner I, Costantino C, Blohmer M, Sundaresan T, Cha J, et al.
medRxiv
. 2023 Oct;
PMID: 37808694
While the development of multiple primary tumors in smokers with lung cancer can be attributed to carcinogen-induced field cancerization, the occurrence of multiple primary tumors in individuals with -mutant lung...
8.
Guo H, Vuille J, Wittner B, Lachtara E, Hou Y, Lin M, et al.
Cell
. 2023 Jun;
186(13):2765-2782.e28.
PMID: 37327786
Cancer is characterized by hypomethylation-associated silencing of large chromatin domains, whose contribution to tumorigenesis is uncertain. Through high-resolution genome-wide single-cell DNA methylation sequencing, we identify 40 core domains that are...
9.
Dubash T, Bardia A, Chirn B, Reeves B, LiCausi J, Burr R, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(1):43-56.
PMID: 37318638
Purpose: Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD)...
10.
Brett J, Dubash T, Johnson G, Niemierko A, Mariotti V, Kim L, et al.
JCO Precis Oncol
. 2023 May;
7:e2200532.
PMID: 37141550
Purpose: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i)....